title: Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone: therapeutic efficacy in a range of experimental nervous system disorders.
abstract: Glutamate neurotransmission is highly regulated, largely by glutamate transporters. In the spinal cord, the glutamate transporter GLT-1 is primarily responsible for glutamate clearance. Downregulation of GLT-1 can occur in activated astrocytes, and is associated with increased extracellular glutamate and neuroexcitation. Among other conditions, astrocyte activation occurs following repeated opioids and in models of chronic pain. If GLT-1 downregulation occurs in these states, GLT-1 could be a pharmacological target for improving opioid efficacy and controlling chronic pain. The present studies explored whether daily intrathecal treatment of rats with ceftriaxone, a beta-lactam antibiotic that upregulates GLT-1 expression, could prevent development of hyperalgesia and allodynia following repeated morphine, reverse pain arising from central or peripheral neuropathy, and reduce glial activation in these models. Ceftriaxone pre-treatment attenuated the development of hyperalgesia and allodynia in response to repeated morphine, and prevented associated astrocyte activation. In a model of multiple sclerosis (experimental autoimmune encephalomyelitis; EAE), ceftriaxone reversed tactile allodynia and halted the progression of motor weakness and paralysis. Similarly, ceftriaxone reversed tactile allodynia induced by chronic constriction nerve injury (CCI). EAE and CCI each significantly reduced the expression of membrane-bound, dimerized GLT-1 protein in lumbar spinal cord, an effect normalized by ceftriaxone. Lastly, ceftriaxone normalized CCI- and EAE-induced astrocyte activation in lumbar spinal cord. Together, these data indicate that increasing spinal GLT-1 expression attenuates opioid-induced paradoxical pain, alleviates neuropathic pain, and suppresses associated glial activation. GLT-1 therefore may be a therapeutic target that could improve available treatment options for patients with chronic pain.
authors.affiliation: Department of Psychology and Neuroscience, Center for Neuroscience, University of Colorado at Boulder, Boulder, CO 80309-0345, USA. khara.ramos@colorado.edu
authors.forename: K M
authors.initials: KM
authors.lastname: Ramos
authors.forename: M T
authors.initials: MT
authors.lastname: Lewis
authors.forename: K N
authors.initials: KN
authors.lastname: Morgan
authors.forename: N Y
authors.initials: NY
authors.lastname: Crysdale
authors.forename: J L
authors.initials: JL
authors.lastname: Kroll
authors.forename: F R
authors.initials: FR
authors.lastname: Taylor
authors.forename: J A
authors.initials: JA
authors.lastname: Harrison
authors.forename: E M
authors.initials: EM
authors.lastname: Sloane
authors.forename: S F
authors.initials: SF
authors.lastname: Maier
authors.forename: L R
authors.initials: LR
authors.lastname: Watkins
mesh_terms: D000818:Animals; D002443:Ceftriaxone / Q000494:pharmacology* / Q000627:therapeutic use*; D004195:Disease Models, Animal; D027342:Excitatory Amino Acid Transporter 2 / Q000096:biosynthesis*; D018698:Glutamic Acid / Q000378:metabolism*; D008297:Male; D010148:Intractable Pain / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013116:Spinal Cord / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology*
chemical_list: D027342:Excitatory Amino Acid Transporter 2; D018698:Glutamic Acid; D002443:Ceftriaxone